Research Square
January 25, 2022
Joseph T. la Torre, Mehdi Mahammadli, Kyle T. Greenway et al.
18 citations
preprint
Abstract Background Currently, personal or familial histories of psychotic symptoms are exclusionary criteria for most psychedelic clinical trials, studies, and treatment programs. This study sought to determine why such an exclusion exists, what the implications of the exclusion criteria are, and if there was agreement in expert opinion. Methods In-depth interviews with 12 experts in the...
International Clinical Psychopharmacology
April 23, 2021
Kyle T. Greenway, Nicolas Garel, Nathalie Goyette et al.
12 citations
Intravenous ketamine is an effective treatment of bipolar depression. One of its most important side-effects is a transient altered state of consciousness commonly referred to as dissociation. These states can be anxiety-provoking, distressing and even treatment-limiting, warranting research into mitigation strategies. In this article, we present two cases that demonstrate the potential of...
Expert Review of Clinical Pharmacology
June 1, 2020
Kyle T. Greenway, Nicolas Garel, Lisa Jerome et al.
87 citations
INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind...
Alvita Sam, Alexander de Foe, Aspasia Stacey Rabba et al.
preprint
Background: Autistic adults are under-investigated in psychedelic research, despite speculated elevated likelihood of substance use for therapeutic and recreational purposes.Aims: This study explored contexts of naturalistic psychedelic use and wellbeing and mental health indicators in a group of Autistic adults using psychedelics for therapeutic purposes, and compared these with the broader...